首页> Frontiers in cardiovascular medicine> Amlexanox reduces new-onset atrial fibrillation risk in sepsis by downregulating S100A12: a Mendelian randomization study.

Amlexanox reduces new-onset atrial fibrillation risk in sepsis by downregulating S100A12: a Mendelian randomization study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Hang,Yang

第一单位： Department of Anesthesiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

作者： Hang,Yang ^[1] ; Lin,Feng ^[2] ; Zhenjie,Jiang ^[1] ; Xiaodan,Wu ^[3] ; Kai,Zeng ^[1]

作者单位： Department of Anesthesiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. ^[1] Department of Hematology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. ^[2] Department of Anesthesiology, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, China. ^[3]

关键词 Mendelian randomization S100A12 amlexanox atrial fibrillation inflammation sepsis

DOI 10.3389/fcvm.2024.1401314

PMID 39444551

发布时间 2024-10-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in cardiovascular medicine

2024年11卷

1401314页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Frontiers in cardiovascular medicine

2024年11卷

1401314页

检索历史清除

Amlexanox reduces new-onset atrial fibrillation risk in sepsis by downregulating S100A12: a Mendelian randomization study.

Frontiers in cardiovascular medicine

相似文献

同项目论文

Frontiers in cardiovascular medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Amlexanox reduces new-onset atrial fibrillation risk in sepsis by downregulating S100A12: a Mendelian randomization study.

Frontiers in cardiovascular medicine

相似文献

同项目论文

Frontiers in cardiovascular medicine

相关期刊

检索历史清除